Recent

% | $
Quotes you view appear here for quick access.

NeuroMetrix Inc. Message Board

SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Thomas Higgins last two stock purchases ......

    by bonkp1 Aug 29, 2015 1:05 PM

    Shai N. Gozani bought stock with approx. 8.5% of his annual pay.

    Sentiment: Strong Buy

  • total up to 2.1% of his annual pay. Not much, but a start.

    Sentiment: Strong Buy

  • Reply to

    Quell sales

    by bonkp1 Aug 28, 2015 3:10 PM

    What the security guard guy?

  • Reply to

    Quell sales

    by bonkp1 Aug 28, 2015 3:10 PM

    twitter slash quellrelief

  • Reply to

    Quell sales

    by bonkp1 Aug 28, 2015 3:10 PM

    Cmon b1, don't leave us hanging. Who did the tweet come from, and what did it say?

    Sentiment: Strong Buy

  • Reply to

    Quell sales

    by bonkp1 Aug 28, 2015 3:10 PM

    interesting tweet after market close

  • Reply to

    Quell sales

    by bonkp1 Aug 28, 2015 3:10 PM

    Very Possible, especially with the marketing company they hired Advantage Health if they can penetrate the big chain pharmacies like CVS, Rite-Aid and Walgreens and get exposure on a few of the online venues like Amazon and Ebay and the captive audience of HSN and QVC they can easily hit that 20K number and probably surpass it in spades.
    GLTA

    Sentiment: Strong Buy

  • Looks like everything rides on continued strength and further market penetration in DPNCheck revenue streams as well as and more importantly Quell sales.

    NURO needs to hit 20,000 AVERAGE unit sales of $270.00 (That's one device and one electrode) This $5.4 million in revenue would fix the balance sheet fast.

    Sentiment: Strong Buy

  • Reply to

    Tallys.....

    by bonkp1 Aug 27, 2015 12:53 PM

    They say they anticipate commercial launch in 2016 due to issues with the regulatory process.

    Sentiment: Strong Buy

  • Reply to

    Tallys.....

    by bonkp1 Aug 27, 2015 12:53 PM

    Its been over a year since they applied for regulatory approval for DPN Check in China, Final approval could come any day, that will surely boost sales of DPN-Check drastically, IMO
    GLTA

    Sentiment: Strong Buy

  • Reply to

    Massive Class Action Lawsuit

    by spree1975 Aug 26, 2015 6:22 PM

    100% spoke with Tom again today and he has reached out to their attorneys and was told this particular junk firm is known for this @#$%^ every day of the week looking for (fishing) a disgruntle investor to now have a plaintiff... Tom's lawyer also said they are often get chased out of the court room... No worries. We are very close to launch.. GL brother

  • Reply to

    Tallys.....

    by bonkp1 Aug 27, 2015 12:53 PM

    Should easily hit 2700 DPNCheck devices sold since launch IMHO(500 this year alone or 18.5% of total units sold since inception)and sell over 140,000 electrode tests this year. Total value on DPNCheck devices and electrodes to be $ 1,849,400.00. $1,149,400.00 in electrodes plus $700,000.00 in device sales.

    In 2014 680 devices sold and 110,000 electrodes sold for total revenue of $1,855,100.00
    My math is slightly off on this 2014 number so I figure electrodes must have been cheaper in that year?

    Sentiment: Strong Buy

  • From 10K 2013 and from 10K 2014:

    2012 DPNCheck and consumable biosensors revenue 1.4 million
    2013 DPNCheck and consumable biosensors revenue 1.3 million
    2014 DPNCheck and consumable biosensors revenue 1.8 million
    *Huge sales force put to rest in early 2013 and now mostly selling to US Medicare Advantage and select overseas markets.

    By end of 2011 80 NC-stat DPNcheck devices placed with customers
    By end of 2012 836 NC-stat DPNcheck devices placed with customers
    By end of 2013 634 NC-stat DPNcheck devices placed with customers.
    By end of 2014 680 NC-stat DPNcheck devices placed with customers.
    1st half of 2015 230 units shipped
    Total sold since launch 2,430

    85,000 tests shipped in 2013
    110,000 tests shipped in 2014
    65,300 tests shipped in 1st half 2015
    *The more devices in service correlates to more tests sold. Current tests/device/year appears to be approx. 50 or 1/week.

    We believe that attractive opportunities are developing in Japan where we received regulatory approval and launched DPNCheck with Omron Healthcare in 2014; in China where we are working with Omron Healthcare on the regulatory process(2016); in Mexico where our distributor Scienta Farma recently received regulatory approval and plans to launch in early 2015; and in the Middle East.

    DPNCheck revenue up 40% in 2014 over 2013. 1.8 million vs. 1.3 million.

    US Medicare Advantage business expanded with approx. 50% growth in tests shipped in 2014 vs. 2013

    DPNCheck revenue in Q2 2015 $416,000.00
    130 DPNCheck devices shipped
    28,500 tests shipped

    DPNCheck revenue in 1st half 2015 $920,000.00
    230 DPNCheck devices shipped
    65,200 tests shipped

    DPNCheck devices are $1,400.00 each

  • Reply to

    DPNCheck studies

    by bonkp1 Aug 27, 2015 11:01 AM

    I am sure they are ramping up and regardless, how hard could it possibly be to duplicate their 6,000 sq/ft manufacturing facility and increase their 15-20 assemblers/packagers. Remember the electrodes are produced offsite by a third party who has plenty off capacity to produce them.

    Sentiment: Strong Buy

  • Reply to

    DPNCheck Value

    by bonkp1 Aug 27, 2015 9:02 AM

    I know that was a cummulative total. I am only trying to reason price points. My above reasoning was wrong and I will now correct. I mistakenly added the 26,000 to the 28,500 Omron sales but now believe it is only 26,000 domestic sales plus 2,500 Omron sales for a total of 28,500 sales(This is further verified by page 15 of the Q2 2015 filing) The Q2 also states 130 DPNCheck devices sold.

    If DPNCheck devices are $1,400.00 each and 130 were sold then that is $182,000.00 for the devices. Subtracting this $182,000.00 from the $416,000.00 DPNCheck revenue in the quarter leaves $234,000.00. Dividing this total by the 28,500 tests shipped in Q2 gives $8.21 per test.(Final answer)

    So in closing then $8.21 per test multiplied by 200,000 Medicare Advantage tests equals $1,642,000.00 in sales SINCE LAUNCH. So 14.25% ($234,000.00)of cummulative Medicare Advantage tests sold in Q2 alone!

    Sentiment: Strong Buy

  • Reply to

    DPNCheck Value

    by bonkp1 Aug 27, 2015 9:02 AM

    Calm down...a milestone is simply a cumulative total. We did not increase qtrly dpn sales by eight fold. Why no one else has corrected you is just as alarming. The good news is 200,000 potential users for quell....not guaranteed but known leads. :-)

    Sentiment: Buy

  • Reply to

    DPNCheck studies

    by bonkp1 Aug 27, 2015 11:01 AM

    I think what will move the stock in the near term will be the new rep firm they signed announcing some mass merchandisers with a national TV campaign to market it....if this rep firm is as plugged in as their website states, should happen sooner rather than later. Can Nuro keep up with a surge in orders would be a great problem to have,

  • There are currently 8 separate ongoing studies that in some cases started in 2011 and all of which are ending this tear or next year. These studies will give further validity and widespread acceptance of DPNCheck.

    Sentiment: Strong Buy

  • Reply to

    DPNCheck Value

    by bonkp1 Aug 27, 2015 9:02 AM

    From 2014 10K:

    We believe that attractive opportunities are developing in Japan where we received regulatory approval and launched DPNCheck with Omron Healthcare in 2014; in China where we are working with Omron Healthcare on the regulatory process; in Mexico where our distributor Scienta Farma recently received regulatory approval and plans to launch in early 2015; and in the Middle East.

    Sentiment: Strong Buy

Must Watch
NURO
0.9202+0.0301(+3.38%)Aug 28 3:59 PMEDT